ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ORGO vs OKUR // 10Y YIELD & FRED MACRO BETA

Organogenesis Holdings Inc. (Class A) (NASDAQ) VS. OnKure Therapeutics Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: ORGO 2 — OKUR 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ORGO VS. OKUR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ORGO OKUR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 17.10% -35.00% +52.10 ORGO /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -23.21% — — TIE /fcf-yield <GO>
Operating Margin 7.90% — — TIE /operating-margins <GO>
Net Profit Margin 6.60% — — TIE /net-margins <GO>
Revenue Growth (YoY) 17.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.09 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 ORGO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 15.6 49.9 -34.31 OKUR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $105.4M $106.1M -$728.7K OKUR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ORGO REV OKUR REV ORGO GROSS % OKUR GROSS % ORGO FCF OKUR FCF
FY 2025 $564.2M $0 — — -$24.5M -$51.9M
FY 2024 $482.0M $0 76.0% — $4.2M -$51.2M
FY 2023 $433.1M $0 — — $30.9M -$34.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ORGO // BETA —
OKUR // BETA —